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Abstract
Background: The Consolidated Standard of Reporting Trials (CONSORT) Guidelines were developed to
support adequate reporting of randomized controlled trials (RCTs).
Method: A systematic review was conducted including RCTs of infectious diseases published in the top general
medical and infectious disease journals in 2010. The level of compliance to flow diagram and its association with the
CONSORT endorsement by the journals were evaluated.
Results: A total of 67 studies were included in the analysis and a half of the studies were HIV/AIDS RCTs.
About 78% of the studies included the flow diagram and 66% of the studies described an intention-to-treat approach.
However, explicit descriptions of the study populations were the most lacking during the follow-up stage. The journals
that endorsed the CONSORT statement had significantly lower odds of including the CONSORT flow diagram as
compared with non-endorsing journals (OR=0.144; 95% CI 0.036-0.575, p<0.05).
Conclusions: About one out of four published RCTs in the top medical- and infectious disease journals did not
include the CONSORT diagram in 2010, and inconsistency in the reporting of the study population was observed.
Clear and complete description of the attrition, especially on the follow-up process, can enhance valid interpretations
of the findings by clinical pharmacists.

Keywords: CONSORT compliance; Intention to treat analysis;
Attrition; Infectious disease
Introduction
The Consolidated Standards of Reporting Trials (CONSORT)
Guidelines were created in 1996 and most recently updated in 2010
[1,2]. The guidelines were specifically developed to alleviate the problem
of inadequate reporting of randomized controlled trials (RCTs), which
is associated with bias in estimating the effectiveness of interventions
[2,3]. CONSORT strongly recommends and encourages transparency
with reporting methods and results so that readers can accurately
interpret and assess strengths and limitations of the studies [4-8].
Several follow-up studies have noted a positive effect of the guideline
recommendations on the overall reporting of RCTs [5,7]. One of the
recommendations of CONSORT is the inclusion of a flow diagram
that maps the path of each study subject through the entire trial, from
randomization to analysis and follow-up [2]. The CONSORT flow
diagram not only enables readers to more easily track the number
of participants, but it also assists in determining if intention-to-treat
(ITT) analysis was carried out by evaluating a structure and process
of the study population in the RCT and its attrition. Although many
journals have adopted CONSORT as part of their submission criteria,
published articles from literature indicate that many RCTs do not
include the recommended CONSORT flow diagram in the publication
[9,10] and even fewer studies reported associations between the
COSORT compliance and the CONSORT endorsement by journals.
As disproportionate attrition of the patients with various reasons
such as missing data, loss to follow up, adverse drug effects, and others,
can distort the initial randomization scheme and potentially threaten
the internal validity of the study, which can subsequently lead to an
inaccurate conclusion and inappropriate application to clinical practice
[11,12], this study was prepared to assess the level of CONSORT
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compliance by including a flow diagram, to describe the extent of
attrition during the stages of study subject enrollment, allocation, loss
to follow-up, and analysis, and to evaluate an association between
the CONSORT compliance and the CONSORT endorsement by
journals. Our study focused on infectious diseases because RCTs in the
diseases often include more than one analytic group, such as clinical or
microbiologic outcomes, which requires additional descriptions about
attrition of their study population.

Methods
Data sources and search
A cross sectional evaluation using a systematic literature search was
conducted among all English publications of RCTs of anti-infective
agents in the top 10 general medicine journals and the top 5 infectious
disease journals with highest impact factors, which yielded a total of 14
journals as one journal belonged to both groups. The journals were the
New England Journal of Medicine, Journal of the American Medical
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Association, British Medical Journal (Clinical Research Ed), Archives
of Internal Medicine, PloS Medicine, Annals of Internal Medicine,
Clinical Infectious Diseases, the Journal of Infectious Diseases, the
Lancet Infectious Diseases, AIDS, Emerging Infectious Diseases
Journal, Annual Review of Medicine, Canadian Medical Association
Journal, and Annals of Medicine Journal. The review was made on
the published articles from January 1, 2010 to December 31, 2010 and
search terms included randomized controlled trials in combination
with the Medical Subject Headings for “anti-infective agents.”
Endorsement status of the CONSORT by the journals in year 2010 was
determined by the endorsement status indicated from the CONSORT
website on the access date [13], communication with the editor’s office
of each journal, and instruction to the authors to adhere to CONSORT
statement from the journal. Priority was given to responses from the
editor’s office, and “endorsed” status was considered if two or more
sources of the information were consistent.

Study selection and data analysis
Medline search identified 129 articles from 14 different journals.
Following exclusion criteria, 67 articles were selected for further review
to determine their eligibility based on the criteria of being 1) randomized
controlled study design and 2) original research on infectious disease.
Compliance to the CONSORT statement on participant flow in the
results section [1,2] was determined by inclusion of one or more
flow diagrams describing the study population. The CONSORT flow
diagram accounted for the stages of enrollment, allocation, follow-up,
and analysis. To further describe the level of CONSORT compliance by
each stage, compliance was determined in three levels (i.e., complete,
partial, and missing). If the study fully accounted for the number of
the participants and gave specific reasons in each stage, the study was
considered “complete” compliance in the specific stage. “Partial”
status was defined if the stage description did not completely provide
information on the number of excluded participants or reasons but
did include some information. “Missing” status was defined if the
stage description did not include any information on the number
of participants or reasons for exclusion. Information on the extent
of attrition, and employment of ITT analysis was collected and
summarized from CONSORT flow diagrams as well as from body text
of the articles.
Analytic goals of our study were primarily reporting results from
the descriptive analyses on frequency or proportion of CONSORT
compliance by stage and journal type. Multivariate logistic regression
was conducted to determine potential predictive factors for CONSORT
compliance of including a flow diagram and adjusted ORs were
calculated. The significance level of the multivariate analysis was set
at 0.05 and the analysis was performed with SPSS statistical software,
version 20 (SPSS Inc, Chicago, IL).

Results
The study identified 129 RCT articles published from January 1st
to December 31st in 2010 from the selected 14 journals and only 67
RCTs from 9 journals met the inclusion criteria (Figure 1). Of the 67
infectious disease RCTs, 52 articles (77.61%) included the CONSORT
flow diagram. Forty-four (65.67%) articles described an ITT approach
in their methods (Figure 1). About a half (50.75%) of the selected
articles were HIV/AIDS, followed by malarial infection (8.96%) or
parasitic infection (8.96%) Table 1.
The selected articles were evaluated for CONSORT compliance
by evaluating the inclusion of participant flow diagrams and the level
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of the compliance in each stage of the CONSORT descriptions. Of
the 52 RCTs that included the CONSORT participant flow diagram,
higher proportions of the articles included ‘complete’ descriptions on
stages of enrollment (40 studies or 76.92%) and allocation (44 studies
or 84.61%). However, smaller number of studies included ‘complete’
descriptions on the follow-up stage (16 studies or 30.76%) Figure 2.
Journals that did not endorse CONSRT guidelines include the
Clinical Infectious Diseases journal, the Lancet Infectious Diseases
journal, and the New England Journal of Medicine journal during the
study period and they accounted 53.7% (36 out of 67 articles) of the
total number of articles (Table 2). Of the 52 articles that included the
CONSORT flow diagram, 33 (64.5%) were published in journals not
endorsing CONSORT Statement in their instruction to the authors
(Table 2). Findings from our study also showed that the CONSORT
endorsement by the journal was a negative predictor for including
CONSORT participant flow diagram. (ORadj=0.144; 95% CI 0.0360.575, p<0.05).

Discussion
Our study provides a snapshot assessment of the level of compliance
to the CONSORT statement on participant flow by including a flow
diagram from published RCTs of infectious diseases in 2010. A
comprehensive CONSORT flow diagram reduces the time for readers
like clinical pharmacists to follow the flow of the study participants
so that key information related to study subjects in each phase of the
clinical trial can be captured so that clinicians could make an accurate
interpretation and assessment of the strengths and limitations of the
findings from RCTs [4-8] to be applied to pharmacy practice.
From the results of our study, over three out of four RCTs included
a CONSORT flow diagram. Our findings corroborate with other
published studies from non-infectious diseases – such as obstetric
anesthesia (89%)[14], respiratory disease (69%) [15], acute and chronic
myeloid leukemia, and myelodysplastic syndromes (89%) [16], and
restless legs syndrome (88.9%) [17]. While our study reported that
majority of the articles with CONSORT participation flow diagrams
were from non-CONSORT endorsing journals, our results are not
consistent to those reported by Hopewell et al. [18] reporting that
90.11% of studies with the diagram were published in CONSORTendorsing journals.
Our review also showed that the reporting of the integral elements
of the RCTs in the flow diagram was lacking. In the elements examined,
i.e. overall number of people screened for study eligibility, the number
of people that were randomized, the number of people allocated to
either control group or intervention group, and the overall number
of people analyzed, variabilities in the level of descriptions about the
study participants were demonstrated, particularly for the numbers
in the follow-up and the analysis phases. Details of the attrition rate
of the participants or those who discontinued the intervention were
poorly accounted for; only 30% of the trials reported the overall
number of lost-to-follow-up, which can lead to bias in estimating
the effectiveness of interventions, thereby undermining the aim of
CONSORT [2,3]. The variability in the clear reporting of the elements
of the flow diagram was not limited to our study. A study by Kehoe
et al on nutrition and pregnancy found that only 31% of their studies
reported the overall number of people screened for study eligibility
[19]. Follow-up analyses as well as analyses of the groups to which
subjects were originally allocated are usually included as part of good
research method practices [20].
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129 articles identified
From 14 journals

58 articles excluded
Non randomized trials (n=55)
No control group (n=3)

71 RCTs reviewed
4 non-infectious disease articles
excluded
67 RCTs selected and analyzed
From 9 journals

CONSORT diagram

ITT analysis

Yes (n = 52)
No (n = 15)

Yes (n =44)
No (n =23)

Number of articles

Figure 1: Flow diagram of RCTs included in the study
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Figure 2: The level of CONSORT compliance*
*Complete: The study fully accounted for the number of the participants and gave reasons. Partial: The study did not completely provided information on the number
of excluded participants or reasons. Missing: The section was not provided.
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Disease Category

Number (%) of articles

HIV/AIDS Infection

34 (50.75%)

Malarial Infection

6 (8.96%)

Parasitic Infection

6 (8.96%)

Respiratory Infection

5 (7.42%)

Surgical Prophylaxis

5 (7.42%)

Other*

11 (16.42 %)

TOTAL

67

Table 1: Distribution of the study articles by infectious disease category
*
Other diseases include sexually transmitted diseases, hepatitis, influenza,
Mycobacterium infection, or other viral infections.

Journal name
(Impact factor)*

CONSORT
Endorsement**

Number (%) of
selected articles

Number (%) of
articles with CONSORT participant
flow diagrams

AIDS (6.557)

Yes

12 (17.91)

7 (13.46)

Ann Intern Med
(16.104)

Yes

1 (1.49)

1 (1.92)

BMJ (16.378)

Yes

2 (2.99)

1 (1.92)

Clin Infect Dis
(9.416)

No

20 (29.85)

17 (32.69)

J Infect Dis (5.778) Yes

10 (14.93)

4 (7.69)

JAMA (30.387)

Yes

3 (4.48)

3 (5.77)

Lancet Infect dis
(19.446)

No

3 (4.48)

3 (5.77)

N Engl J Med
(54.420)

No

13 (19.40)

13 (25.00)

Plos Med (14.000) Yes

3 (4.48)

3 (5.77)

Total

67 articles (100)

52 articles (100)

9 journals

Table 2: Characteristics of selected articles by journal, endorsement of the CONSORT Statement, and inclusion of the CONSORT participant flow diagrams
* Impact factor in 2013
** Endorsement status was collected from the CONSORT website, communication
with the journal, or instructions to the authors.

To achieve an ITT analysis in studies, all randomized subjects must
be included in the final analysis in the arm to which they were allocated,
irrespective of whether subjects received the allocated treatment, left
the study, or failed to comply with treatment regimen [11,20,21]. A
total of 65.67% (44/67) of the RCTs in our study reported an ITT
approach in their methods. Gravel and et al reported a similar result
that 62% of articles reported the use of ITT [22]. This is critical for
interpretation and application of the findings in clinical practice [11].
As argued by many authors, the exclusion of study subjects from final
analysis may favor one treatment group over another and can bias
the results of the study, which can affect the validity of the inferences
drawn from the study [23]. A disproportionate attrition rate threatens
the internal validity of RCTs [4,11,12,24] and it has also been described
that statistical analysis may make unreasonable assumptions when data
are incomplete or missing [25].
Our findings indicate that articles with the CONSORT flow
diagram did not include crucial elements of the RCTs such as numbers
of study participant attrition or numbers in the ITT analyses with
sufficient clarity. Unclear and incomplete descriptions about a RCT’s
study population and its attrition process can be misleading for
clinicians and be a potential source of inaccurate interpretations.
The problem of missing data in RCTs cannot be completely avoided,
but it can be minimized through careful study design [26], and
transparency in attrition descriptions could allow clinicians including
clinical pharmacists to accurately interpret and assess strengths and
limitations of RCTs [7]. The uncertainty related to missing data in a
study can be minimized by carrying out a sensitivity analysis of the
J Pharma Care Health Sys
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missing population to investigate the effect of the missing data from the
assumption made in the ITT analyses [27,28].
This study has a few limitations. Our evaluation was limited to
RCTs involving anti-infective agents, publications in English language,
and trials published in the highest impact factor general medicine and
infectious diseases journals. Therefore, our findings might not be a true
representative of all published studies of RCTs or clinical conditions.
“CONSORT 2010 Explanation and Elaboration: updated guidelines for
reporting parallel group randomized trials” was published 24 March
2010 [3]. Although there was a time gap between the time the updated
guidelines were published and the search of our study, inclusion of the
flow diagram were consistently recommended and the progress of the
trial was divided into four stages of enrollment, allocation, follow-up,
and analysis in the 2001 and 2010 guidelines [1,2].

Conclusion
In conclusion, about one out of four published RCTs in the
highest impact factor medical- and infectious disease journals did
not include the CONSORT participant flow diagrams in 2010 and the
CONSORT endorsement by the journal was not a positive predictor
for the inclusion of the diagram. Clear and complete description of
the attrition, especially on the follow-up process, can enhance valid
interpretations of the findings by clinical pharmacists. Further studies
are needed to explore if similar patterns are observed from other
clinical conditions.
Acknowledgement: This study was supported in part by funding from the
Health Resources and Services Administration grant D34HP6042 and Seoul
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